SynOx clinches $75M to start pivotal testing of ex-Roche cancer candidate
Phase 3AcquisitionPhase 2
SynOx Therapeutics closed a $75-million series B on Monday to fund a potentially registrational trial of its sole pipeline programme to treat tenosynovial giant cell tumour (TGCT), a kind of cancer that affects the soft tissue lining of joints and tendons.
Co-led by Forbion, HealthCap and new investor Bioqube Ventures, the round will go towards the Phase III TANGENT trial of emactuzumab, an anti-CSF-1 receptor monoclonal antibody (mAb).
According to ClinicalTrials.gov, the randomised, double-blind trial is scheduled to start by the end of April and aims to enrol up to 128 patients to receive either an IV infusion of emactuzumab or placebo. The study is expected to wrap in 2027.
SynOx’s parent company, Celleron Therapeutics, acquired exclusive worldwide rights to the mAb from Roche in 2020. A few months later, SynOx was spun out with a €37-million series A financing to develop emactuzumab.
The biotech said that, in a previous study of 63 patients with TGCT, emactuzumab led to an overall response rate of about 71%. The mAb is designed to deplete tumour-associated macrophages within the tumour microenvironment by blocking CSF-1 activation.
“As a highly effective, next-generation therapy with a short treatment cycle, rapid onset and long duration of response, we believe that emactuzumab is differentiated from other agents in development and will provide a much needed and valuable option for patients suffering from this grievous disease,” said CEO Ray Barlow.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.